MalPha
| government-owned corporation | |
| Industry | Pharmaceuticals Biotechnology Medical Equipment Consumer Healthcare |
| Founded | May 28 1910 |
| Headquarters | Epping , United Kingdom of Malgrave |
Area served | Worldwide |
| Revenue |  USD$ 302.35 billion |
| USD$ 7.29 billion | |
| USD$ 2.89 billion | |
| Total assets | USD$ 468.12 billion |
| Total equity | USD$ 425.94 billion |
Number of employees | 379,533 |
| Website | MalPha.ms |
MalPha is a Malgravean pharmaceutical and biotechnology company. It was established shortly after the creation of the nation to facilitate the steady development of pharmaceutical products and other medical advancements, without the need to facilitate stockholders or other private interests.
History
MalPha was one of the smallest state-owned corporations prior to the exodus, with the company mostly focused on developing medication with the limited resources available to the Malgravean people at the time, however, following the discovery of Malgravean Immunodeficiency Disorder in the 50's the company began to grow in importance and size, as treatments needed to be discovered and manufactured to stem the developing sickness.
During the 1970's MalPha also began to branch out into areas of consumer healthcare, with the company negotiating a cooperation agreement with MalMart to develop a new generation of oral healthcare and other products for the company. It is an area of the company that has grown substantially since the expansion of MalMart in the 2000's and is credited with funding a large portion of MalPha's R&D work.
In the early 2000's MalPha was one of the first companies to heavily invest in the Research Colony, with MalPha negotiating with officials in the city of Luban to create a biomedical hub called Remetopia. MalPha has gained national attention over the decades for using peptide therapy in the treatment of Alzheimers alongside immunotherapy and hormone treatments to deal with kinds of cancer, more recently media attention has focused around Emily Lowwe and the project to further develop existing nanotechnology into nanites.
Expansion
Following the end of isolationism MalPha has also attempted to expand internationally, with the company opening research facilities both within Mystria and beyond to try and facilitate treatments for a multitude of non-human races. MalPha has also tried to introduce booster technology, conventional MalPha treatments enhanced with ancestral abilities.
MIDD treatment
Since the 50's MalPha pioneered a series of treatments to cure problems associated with MIDD, however, despite the best efforts of generations of specialised research teams a cure proved elusive. It took until the success of the Crescent Expedition for a treatment to be found, with MalPha quickly creating a treatment program from the results of the successful expedition.